Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 30;12(8):1826-1829.
doi: 10.21037/tlcr-23-288. Epub 2023 Jul 28.

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?

Lara Kujtan  1 , Janakiraman Subramanian  2
Affiliations
Editorial

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?

Lara Kujtan et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Lung cancer; MET; epidermal growth factor receptor (EGFR); telisotuzumab vedotin.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-288/coif). JS received consulting fees from Astra Zeneca, Jazz, Janssen, G1 therapeutics, Cardinal, Daiichi, Beigene, Takeda, Oncohost, Blueprint, GLG, Guidepoint, and payments or honoraria from Astra Zeneca, Jazz, Janssen, G1 therapeutics. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Selected target therapies of the c-Met receptor. HGF, hepatocyte growth factor; PSI, plexin-semaphorin-integrin; IPT, immunoglobulin-like, plexin, transcription factors; TK, tyrosine kinase; MET, MMNG HOS transforming gene; TKI, tyrosine kinase inhibitor.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Fu J, Su X, Li Z, et al. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 2021;40:4625-51. 10.1038/s41388-021-01863-w - DOI - PubMed
    1. Liang H, Wang M. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. Onco Targets Ther 2020;13:2491-510. 10.2147/OTT.S231257 - DOI - PMC - PubMed
    1. Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:944-57. 10.1056/NEJMoa2002787 - DOI - PubMed
    1. Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med 2020;383:931-43. 10.1056/NEJMoa2004407 - DOI - PMC - PubMed
    1. Krebs M, Spira AI, Cho BC, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. J Clin Oncol 2022;40:9008.